Review



surrogate viral neutralization test c-pass genscript svnt  (GenScript corporation)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    GenScript corporation surrogate viral neutralization test c-pass genscript svnt
    <t>Neutralization</t> capacity of sera from infected and non-infected individuals against SARS-CoV-2 variants before and after vaccination. The neutralization activity of sera from infected individuals ( n = 10) and non-infected ones ( n = 21) before and after vaccination was evaluated against the six variants of concern. Dotted lines indicate the limit of detection of the sVNT assay, where the percentage of signal inhibition is determined (≥30% indicates a positive result). A normality test (Shapiro–Wilk) was performed for all datasets in order to assess the distribution of the data. The significance threshold for all analyses was set at p < 0.05. ( A ). Neutralization activity of sera from infected individuals ( n = 10) before vaccination. A one-way ANOVA test with Dunnett’s multiple comparisons test was performed between each of the variants. ( B ). Neutralization activity of sera from healthy individuals ( n = 21) after receiving the 1st vaccine dose. A one-way ANOVA test with Dunn’s Kruskal–Wallis multiple comparisons test was performed between each of the variants. ( C ). Neutralization activity of sera from infected individuals ( n = 10) after receiving the first vaccine dose. A one-way ANOVA test with Dunnett’s multiple comparisons test was performed between each of the variants. ( D ). Neutralization activity of sera from healthy individuals ( n = 21) after receiving the 2nd vaccine dose. A one-way ANOVA test with Dunn’s Kruskal–Wallis multiple comparisons test was performed between each of the variants. ( E ). Neutralization activity of sera from infected individuals ( n = 10) after receiving the 2nd vaccine dose. A one-way ANOVA test with Dunnett’s multiple comparisons test was performed between each of the variants. ( F ). Neutralization activity of sera from vaccinated individuals, pre-exposed ( n = 10, depicted in circles) and healthy ( n = 21, depicted in squares), after receiving the 2nd dose was evaluated. A one-way ANOVA test with Dunn’s Kruskal–Wallis multiple comparisons test was performed between each of the variants.
    Surrogate Viral Neutralization Test C Pass Genscript Svnt, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/surrogate viral neutralization test c-pass genscript svnt/product/GenScript corporation
    Average 90 stars, based on 1 article reviews
    surrogate viral neutralization test c-pass genscript svnt - by Bioz Stars, 2026-06
    90/100 stars

    Images

    1) Product Images from "Limited Impact of Delta Variant’s Mutations on the Effectiveness of Neutralization Conferred by Natural Infection or COVID-19 Vaccines in a Latino Population"

    Article Title: Limited Impact of Delta Variant’s Mutations on the Effectiveness of Neutralization Conferred by Natural Infection or COVID-19 Vaccines in a Latino Population

    Journal: Viruses

    doi: 10.3390/v13122405

    Neutralization capacity of sera from infected and non-infected individuals against SARS-CoV-2 variants before and after vaccination. The neutralization activity of sera from infected individuals ( n = 10) and non-infected ones ( n = 21) before and after vaccination was evaluated against the six variants of concern. Dotted lines indicate the limit of detection of the sVNT assay, where the percentage of signal inhibition is determined (≥30% indicates a positive result). A normality test (Shapiro–Wilk) was performed for all datasets in order to assess the distribution of the data. The significance threshold for all analyses was set at p < 0.05. ( A ). Neutralization activity of sera from infected individuals ( n = 10) before vaccination. A one-way ANOVA test with Dunnett’s multiple comparisons test was performed between each of the variants. ( B ). Neutralization activity of sera from healthy individuals ( n = 21) after receiving the 1st vaccine dose. A one-way ANOVA test with Dunn’s Kruskal–Wallis multiple comparisons test was performed between each of the variants. ( C ). Neutralization activity of sera from infected individuals ( n = 10) after receiving the first vaccine dose. A one-way ANOVA test with Dunnett’s multiple comparisons test was performed between each of the variants. ( D ). Neutralization activity of sera from healthy individuals ( n = 21) after receiving the 2nd vaccine dose. A one-way ANOVA test with Dunn’s Kruskal–Wallis multiple comparisons test was performed between each of the variants. ( E ). Neutralization activity of sera from infected individuals ( n = 10) after receiving the 2nd vaccine dose. A one-way ANOVA test with Dunnett’s multiple comparisons test was performed between each of the variants. ( F ). Neutralization activity of sera from vaccinated individuals, pre-exposed ( n = 10, depicted in circles) and healthy ( n = 21, depicted in squares), after receiving the 2nd dose was evaluated. A one-way ANOVA test with Dunn’s Kruskal–Wallis multiple comparisons test was performed between each of the variants.
    Figure Legend Snippet: Neutralization capacity of sera from infected and non-infected individuals against SARS-CoV-2 variants before and after vaccination. The neutralization activity of sera from infected individuals ( n = 10) and non-infected ones ( n = 21) before and after vaccination was evaluated against the six variants of concern. Dotted lines indicate the limit of detection of the sVNT assay, where the percentage of signal inhibition is determined (≥30% indicates a positive result). A normality test (Shapiro–Wilk) was performed for all datasets in order to assess the distribution of the data. The significance threshold for all analyses was set at p < 0.05. ( A ). Neutralization activity of sera from infected individuals ( n = 10) before vaccination. A one-way ANOVA test with Dunnett’s multiple comparisons test was performed between each of the variants. ( B ). Neutralization activity of sera from healthy individuals ( n = 21) after receiving the 1st vaccine dose. A one-way ANOVA test with Dunn’s Kruskal–Wallis multiple comparisons test was performed between each of the variants. ( C ). Neutralization activity of sera from infected individuals ( n = 10) after receiving the first vaccine dose. A one-way ANOVA test with Dunnett’s multiple comparisons test was performed between each of the variants. ( D ). Neutralization activity of sera from healthy individuals ( n = 21) after receiving the 2nd vaccine dose. A one-way ANOVA test with Dunn’s Kruskal–Wallis multiple comparisons test was performed between each of the variants. ( E ). Neutralization activity of sera from infected individuals ( n = 10) after receiving the 2nd vaccine dose. A one-way ANOVA test with Dunnett’s multiple comparisons test was performed between each of the variants. ( F ). Neutralization activity of sera from vaccinated individuals, pre-exposed ( n = 10, depicted in circles) and healthy ( n = 21, depicted in squares), after receiving the 2nd dose was evaluated. A one-way ANOVA test with Dunn’s Kruskal–Wallis multiple comparisons test was performed between each of the variants.

    Techniques Used: Neutralization, Infection, Activity Assay, Inhibition



    Similar Products

    surrogate viral neutralization test c-pass genscript svnt  (GenScript corporation)
    90
    GenScript corporation surrogate viral neutralization test c-pass genscript svnt
    <t>Neutralization</t> capacity of sera from infected and non-infected individuals against SARS-CoV-2 variants before and after vaccination. The neutralization activity of sera from infected individuals ( n = 10) and non-infected ones ( n = 21) before and after vaccination was evaluated against the six variants of concern. Dotted lines indicate the limit of detection of the sVNT assay, where the percentage of signal inhibition is determined (≥30% indicates a positive result). A normality test (Shapiro–Wilk) was performed for all datasets in order to assess the distribution of the data. The significance threshold for all analyses was set at p < 0.05. ( A ). Neutralization activity of sera from infected individuals ( n = 10) before vaccination. A one-way ANOVA test with Dunnett’s multiple comparisons test was performed between each of the variants. ( B ). Neutralization activity of sera from healthy individuals ( n = 21) after receiving the 1st vaccine dose. A one-way ANOVA test with Dunn’s Kruskal–Wallis multiple comparisons test was performed between each of the variants. ( C ). Neutralization activity of sera from infected individuals ( n = 10) after receiving the first vaccine dose. A one-way ANOVA test with Dunnett’s multiple comparisons test was performed between each of the variants. ( D ). Neutralization activity of sera from healthy individuals ( n = 21) after receiving the 2nd vaccine dose. A one-way ANOVA test with Dunn’s Kruskal–Wallis multiple comparisons test was performed between each of the variants. ( E ). Neutralization activity of sera from infected individuals ( n = 10) after receiving the 2nd vaccine dose. A one-way ANOVA test with Dunnett’s multiple comparisons test was performed between each of the variants. ( F ). Neutralization activity of sera from vaccinated individuals, pre-exposed ( n = 10, depicted in circles) and healthy ( n = 21, depicted in squares), after receiving the 2nd dose was evaluated. A one-way ANOVA test with Dunn’s Kruskal–Wallis multiple comparisons test was performed between each of the variants.
    Surrogate Viral Neutralization Test C Pass Genscript Svnt, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/surrogate viral neutralization test c-pass genscript svnt/product/GenScript corporation
    Average 90 stars, based on 1 article reviews
    surrogate viral neutralization test c-pass genscript svnt - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Neutralization capacity of sera from infected and non-infected individuals against SARS-CoV-2 variants before and after vaccination. The neutralization activity of sera from infected individuals ( n = 10) and non-infected ones ( n = 21) before and after vaccination was evaluated against the six variants of concern. Dotted lines indicate the limit of detection of the sVNT assay, where the percentage of signal inhibition is determined (≥30% indicates a positive result). A normality test (Shapiro–Wilk) was performed for all datasets in order to assess the distribution of the data. The significance threshold for all analyses was set at p < 0.05. ( A ). Neutralization activity of sera from infected individuals ( n = 10) before vaccination. A one-way ANOVA test with Dunnett’s multiple comparisons test was performed between each of the variants. ( B ). Neutralization activity of sera from healthy individuals ( n = 21) after receiving the 1st vaccine dose. A one-way ANOVA test with Dunn’s Kruskal–Wallis multiple comparisons test was performed between each of the variants. ( C ). Neutralization activity of sera from infected individuals ( n = 10) after receiving the first vaccine dose. A one-way ANOVA test with Dunnett’s multiple comparisons test was performed between each of the variants. ( D ). Neutralization activity of sera from healthy individuals ( n = 21) after receiving the 2nd vaccine dose. A one-way ANOVA test with Dunn’s Kruskal–Wallis multiple comparisons test was performed between each of the variants. ( E ). Neutralization activity of sera from infected individuals ( n = 10) after receiving the 2nd vaccine dose. A one-way ANOVA test with Dunnett’s multiple comparisons test was performed between each of the variants. ( F ). Neutralization activity of sera from vaccinated individuals, pre-exposed ( n = 10, depicted in circles) and healthy ( n = 21, depicted in squares), after receiving the 2nd dose was evaluated. A one-way ANOVA test with Dunn’s Kruskal–Wallis multiple comparisons test was performed between each of the variants.

    Journal: Viruses

    Article Title: Limited Impact of Delta Variant’s Mutations on the Effectiveness of Neutralization Conferred by Natural Infection or COVID-19 Vaccines in a Latino Population

    doi: 10.3390/v13122405

    Figure Lengend Snippet: Neutralization capacity of sera from infected and non-infected individuals against SARS-CoV-2 variants before and after vaccination. The neutralization activity of sera from infected individuals ( n = 10) and non-infected ones ( n = 21) before and after vaccination was evaluated against the six variants of concern. Dotted lines indicate the limit of detection of the sVNT assay, where the percentage of signal inhibition is determined (≥30% indicates a positive result). A normality test (Shapiro–Wilk) was performed for all datasets in order to assess the distribution of the data. The significance threshold for all analyses was set at p < 0.05. ( A ). Neutralization activity of sera from infected individuals ( n = 10) before vaccination. A one-way ANOVA test with Dunnett’s multiple comparisons test was performed between each of the variants. ( B ). Neutralization activity of sera from healthy individuals ( n = 21) after receiving the 1st vaccine dose. A one-way ANOVA test with Dunn’s Kruskal–Wallis multiple comparisons test was performed between each of the variants. ( C ). Neutralization activity of sera from infected individuals ( n = 10) after receiving the first vaccine dose. A one-way ANOVA test with Dunnett’s multiple comparisons test was performed between each of the variants. ( D ). Neutralization activity of sera from healthy individuals ( n = 21) after receiving the 2nd vaccine dose. A one-way ANOVA test with Dunn’s Kruskal–Wallis multiple comparisons test was performed between each of the variants. ( E ). Neutralization activity of sera from infected individuals ( n = 10) after receiving the 2nd vaccine dose. A one-way ANOVA test with Dunnett’s multiple comparisons test was performed between each of the variants. ( F ). Neutralization activity of sera from vaccinated individuals, pre-exposed ( n = 10, depicted in circles) and healthy ( n = 21, depicted in squares), after receiving the 2nd dose was evaluated. A one-way ANOVA test with Dunn’s Kruskal–Wallis multiple comparisons test was performed between each of the variants.

    Article Snippet: To determine the neutralizing activity of antibodies against SARS-CoV-2, we used a surrogate viral neutralization test (C-Pass GenScript sVNT, Piscataway, NJ, USA) according to the manufacturer’s instructions [ , , ].

    Techniques: Neutralization, Infection, Activity Assay, Inhibition